One of the at-home ketamine industry’s biggest boosters has turned bearish, calling for caution among patients and providers and withdrawing his endorsement of the practice. “After being at the forefront of at-home ketamine treatment, recent findings, like the case study of unintentional overdose via telehealth have led me to reevaluate,” said Juan Pablo Cappello, who founded at-home ketamine…


Previous articlePT491 – Drug Development, The State of Biotech, and Exploring Non-Hallucinogenic Compounds
Next articlePT492 – Alien Abductions and Parallel Realities: How Do You Validate the Radically Ineffable?